• Retrospective Description of the Safety and Efficacy of Filgrastim-sndz as a Front-line Mobilization Agent in Combination with Plerixafor followed by Post autologous stem cell infusion use for Autologous peripheral blood stem transplantation in Multiple Myeloma

      McBride, Ali; Sandoval, Anthony; College of Pharmacy, The University of Arizona (The University of Arizona., 2018)
      Purpose Mobilization of hematopoietic stem cells, which has largely replaced bone marrow harvesting as a source of hematopoietic stem cells, utilizing filgrastim and/or plerixafor for peripheral blood stem cell collection for autologous stem cell transplantation. Current data has shown equicoval efficacy with G-CSF based mobilization, however, there has been little data with the combination of a biosimilar and plerixafor in upfront stem cell mobilization. Here we evaluate our institutional outcomes in this setting. Methods This study was a descriptive retrospective chart review. This study included all patients treated with filgrastin-sndz and filgrastim from January 1st 2016 to December 31st 2017, diagnosed with multiple myeloma. There was a total of 48 patients included in the study that met all of the criteria. The CD34+ cells/kg count and adverse events were all analyzed Results A total of 46 patients participated in this study. The goal of it was to collect an average of CD34+ stem cells > 7 x 106/kg. The average collected CD34+ stem cells was 14.7 x 106/kg. The average number of apheresis sessions was 3.59 and none of the patients has an adverse effect from the infusion of filgrastim-sdnz. The average days to 500 ANC and was 13.54 and the average days to platelet count of 50,000 was 22.82. Conclusions Patients treated with filgrastin-sndz had the expected outcomes and had similar adverse reactions to that of filgrastim when compared to other studies.